Trial of HeartNet Stopped Due to Lack of Change in Peak VO2
Major Finding: At 6 months, patients with stage C heart failure who were treated with the HeartNet device experienced a significant reduction of serious heart failure events, compared with patients who received standard medical care alone (HR, 1.9).
Data Source: A study of 217 patients enrolled in the PEERLESS-HF trial.
Disclosures: The study was funded by Paracor Medical Inc. Dr. Abraham disclosed that he is a paid consultant for the company.
He noted that there was nonsignificant evidence of reverse remodeling at 6 months that favored the treatment group. There was also a significant reduction of serious heart failure events in the treatment group, compared with the control group. “In a subgroup of patients with CRT at baseline, there appeared to be a better reduction in the serious heart failure events,” he added. “We believe that these findings support undertaking a clinical trial that targets this patient population.”
The trial was sponsored by Paracor Medical Inc. Dr. Abraham disclosed that he is a paid consultant for the company.
